EUVIMEDEUVIMED entdecken
Crossref

Metabolic dysfunction-associated fatty liver disease and its clinical implications in heart failure

Yoshinori Suzuki, Tomofumi Misaka, Satoshi Okochi, Ryo Ogawara, Yu Sato, Tetsuro Yokokawa, Akihiko Sato, Takeshi Shimizu, Takamasa Sato, Masayoshi Oikawa, Atsushi Kobayashi, Akiomi Yoshihisa und 1 weitere

FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · 2026

DOI: 10.5387/fms.26-00009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2026. Verfasst von Yoshinori Suzuki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Fukushima Medical University. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background:Heart-liver metabolic crosstalk contributes to heart failure pathophysiology. Metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed as a new disease entity based on positive metabolic criteria. However, the clinical implications of MAFLD in heart failure remain to be fully elucidated.Methods and Results:We enrolled 457 hospitalized patients with symptomatic stage C/D heart failure who underwent abdominal ultrasonography for liver assessment. MAFLD was diagnosed based on the presence of hepatic steatosis and metabolic dysfunction. Overall, 20.1% of patients met the criteria for MAFLD. Patients with MAFLD were younger, had higher tricuspid annular plane systolic excursion (TAPSE), and lower B-type natriuretic peptide levels compared to those without MAFLD. In multivariate logistic regression analysis, TAPSE remained independently associated with MAFLD. During a median follow-up period of 1127 days, Kaplan-Meier analysis demonstrated that patients with MAFLD showed a higher event-free survival from all-cause mortality, but not from composite cardiac events. In multivariable Cox proportional hazards analysis, MAFLD was not independently associated with all-cause mortality.Conclusions:MAFLD was common among the hospitalized patients with heart failure. Although MAFLD appeared to be associated with lower overall mortality, MAFLD was not independently associated with mortality from any cause or future cardiac events.

Schlagwörter

Stichwörter der Autor:innen

MAFLDfatty liverheart failureprognosis

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Fukushima Medical University.
  • Department of Community Cardiovascular Medicine, Fukushima Medical University.
  • Department of Clinical Laboratory Sciences, Fukushima Medical University School of Health Sciences.

Zitieren

APA

Suzuki, Y., Misaka, T., Okochi, S., Ogawara, R., Sato, Y., Yokokawa, T., Sato, A., Shimizu, T., Sato, T., Oikawa, M., Kobayashi, A., Yoshihisa, A., & Takeishi, Y. (2026). Metabolic dysfunction-associated fatty liver disease and its clinical implications in heart failure. FUKUSHIMA JOURNAL OF MEDICAL SCIENCE. https://doi.org/10.5387/fms.26-00009

Vancouver

Suzuki Y, Misaka T, Okochi S, Ogawara R, Sato Y, Yokokawa T, et al. Metabolic dysfunction-associated fatty liver disease and its clinical implications in heart failure. FUKUSHIMA JOURNAL OF MEDICAL SCIENCE. 2026. doi:10.5387/fms.26-00009

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Yoshinori and Misaka, Tomofumi and Okochi, Satoshi and Ogawara, Ryo and Sato, Yu and Yokokawa, Tetsuro and Sato, Akihiko and Shimizu, Takeshi and Sato, Takamasa and Oikawa, Masayoshi and Kobayashi, Atsushi and Yoshihisa, Akiomi and Takeishi, Yasuchika},
  title = {Metabolic dysfunction-associated fatty liver disease and its clinical implications in heart failure},
  journal = {FUKUSHIMA JOURNAL OF MEDICAL SCIENCE},
  year = {2026},
  doi = {10.5387/fms.26-00009}
}
Kostenlos starten →